A Wall Street Journal article looks at the pros and cons of direct-to-consumer genetic tests, such as Health Compass, a test offered by San Francisco Bay Area-based Navigenics and available early next year. Despite the fact that these tests can help predict disease susceptibility, some criticisms of include skepticism about their scientific accuracy, high prices (Navigenics is charging $2,500 for their test), insurance, and privacy issues. "Besides questions about accuracy, there is also the issue of how useful the answers will be," writes the WSJ. "There’s no evidence, many physicians say, that people will act on such information to lead healthier lives."
What If I Already Spent That $2,500 On New Lab Equipment?
Nov 06, 2007